Vaginitis Therapeutics Market - By Product (Anti-fungal, Anti-bacterial, Hormone), By Type (Over-The-Counter (OTC), Prescription (Rx)) and By Region (North America, Asia Pacific, Europe, Middle East & Africa and Latin America) - Industry Analysis, Opportunity and Forecast 2020 To 2027
Published Date: May 2021
No. of Pages: 181
Status: Published
Report Code: ARI100606
Vaginitis is a commonly occurring medical condition in women that is associated with significant morbidity and complications previously undetected. Over the past few years comprehensive work has contributed to the advancement of diagnostic methods and treatment modalities for all types of vaginitis. Vaginitis is a vaginal infection which can cause itching, discharge and pain. The main causes of vaginitis include candida or 'yeast' infections, bacterial vaginosis, tyrichomoniasis vaginitis, chlamydia vaginitis, and viral vaginitis. Around one third of women worldwide experience symptoms of vaginitis at some point in their lifetime.
Different governmental and non-governmental organisations such as the World Health Organization and the European Institute of Women's Health (EIWH) have taken steps to raise awareness of women's health issues. Continuous research and development efforts by various companies and growing women's lifestyle habits across the globe, such as smoking and alcohol consumption, are main drivers of business growth.
Leading Companies in this industry are: Pfizer, Inc.; Merck & Co.; Novartis AG; Bayer AG; Lupin Pharmaceuticals, Inc.; Symbiomix Therapeutics, Inc.; Mission Pharmacal Company, Abbott Laboratories, GlaxoSmithKline plc, Sanofi, Novartis AG.
Many of these businesses are taking approaches, such as partnerships, new product growth, M&A, expansion of market in developing regions. Lupin Pharmaceuticals, for example, purchased Symbiomix Therapeutics in October 2017 to strengthen its drug line. As a strategic move, Pfizer Inc. revealed in October 2017 the study of a potential option to spin off their Consumer Healthcare Business.
Product-based demand for vaginitis therapeutics is segmented into drug-dependent anti-fungal, antibacterial, and hormone. The Anti-bacterial segment holds the biggest market share due to rising cases of bacterial vaginosis. It is classified as Over-The-Counter (OTC) and Prescription (Rx) by form on the basis of origin. Of these, the recommended form holds the largest market share due to improved effectiveness and protection against serious and persistent vaginitis.
North America dominated the regional market and stood at USD 861.2 million. Established healthcare infrastructure in this region along with a high prevalence of diseases and the presence of key manufacturers is a major factor that is responsible for its greater share. Through the introduction of new medicines and the expansion of more effective and advanced technology, Europe is the second leading market in vaginitis therapeutics. The Asia Pacific market for vaginitis therapeutics is also expected to see rapid growth due to increased spending on health care, Western lifestyle acceptance, and increasing research and development.
Analyst Commentary
In 2020, more than 13 out of every 100 women were smokers of cigarettes according to the Centers for Disease Control and Prevention (CDC). Researchers have been sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) to improve the yeast infection test to provide effective anti-fungal treatment. In addition, NICHD researchers in the Division of Intramural Population Health Research (DIPHR) are using previous and newly collected data to explore various aspects of the association between bacterial vaginosis and outcome of pregnancy. The increase in accurate diagnosis research and development activities is projected to boost market growth.
Women are particularly susceptible to vaginitis during reproductive age; vaginitis may result from a shift in the balance of bacteria and yeast present in the vagina. Owing to growing numbers of women of reproductive age across the globe and shifts in dietary habits, the global demand for vaginitis therapeutics is expected to expand during the forecast years. Various policy interventions for women's public health services such as an increase in total health care expenditures are also driving the vaginitis therapeutics market. The market is likely to be adversely impacted by the high research and development costs involved as well as the difficulties of drug production in developing economies.
During the forecast period, increasing resistance to conventional antibiotics is projected to be the key driver of the market for vaginitis therapeutics. Increasing use of antibiotics in the treatment of various infections and diseases and health disorders for women is likely to accelerate the growth of the demand for vaginitis therapeutics during the forecast period.
Increasing demand for conventional antibiotic alternatives is likely to increase competition between market players in the market for vaginitis therapeutics.
Segmentation
On the basis of Product, the demand for vaginitis therapeutics is segmented into anti-fungal, anti-bacterial, and hormone dependent on medication. Due to growing cases of bacterial vaginosis, the Anti-bacterial segment holds the largest market share. In 2017, the anti-bacterial market was estimated at USD 900 million in terms of revenue. About 21 million people were reported to have suffered from this epidemic. Drugs used to treat metronidazole, clindamycin, and tinidazole, the bacterial vaginosis.
While this segment of hormonal treatment is expected to witness the fastest growth over the forecast period. Some of the hormone therapies are only available through prescription. It is expected the presence of strong pipeline drugs would fuel the fastest growth in the segment over the forecast period.
On the Basis of Type, it is categorized by form into Over-The-Counter (OTC) and Prescription (Rx) it. Of these, recommended form represents the largest market share due to improved effectiveness and protection for serious and recurrent vaginitis. Thanks to the presence of a wide variety of OTC products, such as vaginal creams, gels and others, OTC is expected to grow at a CAGR of 8.7 percent over the predicted period. In addition, the FDA has approved treatment options for moderate vaginitis for direct use with non-prescribed drugs. Those include in the form of cream, capsules, and suppositories, tioconazole miconazole, clotrimazole, and butoconazole.
Regional Analysis
In 2017 North America led the world market and was valued at USD 861.2 million. Developed healthcare infrastructure in this area together with high disease prevalence and the involvement of key manufacturers is a major factor responsible for its greater share. Other factors, such as good policy initiatives and an increasing target population, are also driving market growth.
Through the introduction of new medicines and the expansion of more effective and advanced technology, Europe is the second leading market in vaginitis therapeutics. The Asia Pacific market for vaginitis therapeutics is also expected to see rapid growth due to increased spending on health care, Western lifestyle acceptance, and increasing research and development.
During the forecast era, Asia Pacific is expected to experience the highest growth with CAGR of about 9.6 per cent. It is due to high unmet health needs, increased disposable income, increased early diagnostic awareness, and availability of successful drugs in developing countries like India and China.
TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data Component
2.3.1. Secondary Component
2.3.1.1. Preliminary data mining
2.3.2. Primary Component
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Vaginitis Therapeutics Market
Chapter 5. Global Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027(USD Billion)
5.1. Global Vaginitis Therapeutics Market Share, By Product, 2015 - 2027 (USD Billion)
5.1.1. Anti-Fungal
5.1.1.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.1.2. Anti-Bacterial
5.1.2.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.1.3. Hormonal
5.1.3.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.1.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
Chapter 6. Global Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027(USD Billion)
6.1. Global Vaginitis Therapeutics Market Share, By Type, 2015 - 2027 (USD Billion)
6.1.1. Over-The-Counter (OTC)
6.1.1.1. Market Type and Projections,2015 - 2027 (USD Billion)
6.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
6.1.2. Prescription (Rx)
6.1.2.1. Market Type and Projections, 2015 - 2027 (USD Billion)
6.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
Chapter 7. Global Vaginitis Therapeutics Market Overview, By Geography, 2015 - 2027(USD Billion)
7.1. Global Vaginitis Therapeutics Market Share, By Geography, 2015 - 2027(USD Billion)
7.1.1. Market Type and projections, by Countries, 2015 - 2027 (USD Billion)
7.1.2. Market Share and CAGR Comparison, by Countries, 2020 - 2027 (%)
Chapter 8. North America Vaginitis Therapeutics Market Overview, By Countries, 2015 - 2027(USD Billion)
8.1. North America Vaginitis Therapeutics Market Overview, 2015 - 2027 (USD Billion)
8.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
8.1.2. North America Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
8.1.3. North America Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
8.1.4. North America Vaginitis Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
8.1.4.1. U.S. Vaginitis Therapeutics Market Overview, 2015 - 2027 (USD Billion)
8.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
8.1.4.1.2. U.S. Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
8.1.4.1.3. U.S. Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
8.1.4.2. Canada Vaginitis Therapeutics Market Overview, 2015 - 2027 (USD Billion)
8.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Billion)
8.1.4.2.2. Canada Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
8.1.4.2.3. Canada Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
8.1.4.3. Mexico Vaginitis Therapeutics Market Overview, 2015 - 2027 (USD Billion)
8.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Billion)
8.1.4.3.2. Mexico Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
8.1.4.3.3. Mexico Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
Chapter 9. Europe Vaginitis Therapeutics Market Overview, By Countries, 2015 - 2027(USD Billion)
9.1. Europe Vaginitis Therapeutics Market Overview, 2015 - 2027 (USD Billion)
9.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
9.1.2. Europe Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
9.1.3. Europe Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
9.1.4. Europe Skin Care Types Market Overview, By Countries, 2015 - 2027 (USD Billion)
9.1.4.1. Germany
9.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
9.1.4.1.2. Germany Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027(USD Billion)
9.1.4.1.3. Germany Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027(USD Billion)
9.1.4.2. France
9.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Billion)
9.1.4.2.2. France Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027(USD Billion)
9.1.4.2.3. France Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027(USD Billion)
9.1.4.3. UK
9.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Billion)
9.1.4.3.2. UK Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027(USD Billion)
9.1.4.3.3. UK Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027(USD Billion)
9.1.4.4. Italy
9.1.4.4.1. Market Type and projections, 2015 - 2027 (USD Billion)
9.1.4.4.2. Italy Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027(USD Billion)
9.1.4.4.3. Italy Vaginitis Therapeutics Market Overview, By Type 2015 - 2027(USD Billion)
9.1.4.5. Spain
9.1.4.5.1. Market Type and projections, 2015 - 2027 (USD Billion)
9.1.4.5.2. Spain Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027(USD Billion)
9.1.4.5.3. Spain Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027(USD Billion)
9.1.4.6. Rest of Europe
9.1.4.6.1. Market Type and projections, 2015 – 2027
9.1.4.6.2. Rest of Europe Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027(USD Billion)
9.1.4.6.3. Rest of Europe Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027(USD Billion)
Chapter 10. Asia Pacific Vaginitis Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
10.1. Asia Pacific Vaginitis Therapeutics Market Overview, 2015 - 2027 (USD Billion)
10.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
10.1.2. Asia Pacific Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
10.1.3. Asia Pacific Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
10.1.4. Asia Pacific Vaginitis Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
10.1.4.1. India
10.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
10.1.4.1.2. India Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027(USD Billion)
10.1.4.1.3. India Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
10.1.4.2. China
10.1.4.2.1. Market Type and projections, 2015 - 2027(USD Billion)
10.1.4.2.2. China Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027(USD Billion)
10.1.4.2.3. China Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
10.1.4.3. Japan
10.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Billion)
10.1.4.3.2. Japan Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027(USD Billion)
10.1.4.3.3. Japan Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027(USD Billion)
10.1.4.4. South Korea
10.1.4.4.1. Market Type and projections, 2015 - 2027(USD Billion)
10.1.4.4.2. South Korea Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027(USD Billion)
10.1.4.4.3. South Korea Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
10.1.4.5. Rest of Asia Pacific
10.1.4.5.1. Market Type and projections, 2015 - 2027 (USD Billion)
10.1.4.5.2. Rest of Asia Pacific Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027(USD Billion)
10.1.4.5.3. Rest of Asia Pacific Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
Chapter 11. Middle East & Africa Vaginitis Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
11.1. Middle East & Africa Vaginitis Therapeutics Market Overview, 2015 - 2027 (USD Billion)
11.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
11.1.2. Middle East & Africa Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
11.1.3. Middle East & Africa Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
11.1.4. Middle East & Africa Vaginitis Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
11.1.4.1. GCC
11.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
11.1.4.1.2. GCC Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
11.1.4.1.3. GCC Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
11.1.4.2. South Africa
11.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Billion)
11.1.4.2.2. South Africa Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
11.1.4.2.3. South Africa Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
11.1.4.3. Rest of Middle East & Africa
11.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Billion)
11.1.4.3.2. Rest of Middle East & Africa Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
11.1.4.3.3. Rest of Middle East & Africa Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
Chapter 12. South America Vaginitis Therapeutics Market Overview, By Countries, 2015 - 2027 (USD Billion)
12.1. South America Vaginitis Therapeutics Market Overview, 2015 - 2027 (USD Billion)
12.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
12.1.2. South America Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
12.1.3. South America Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
12.1.4. South America Vaginitis Therapeutics Market Overview, By Countries, 2015- 2026 (USD Billion)
12.1.5. Brazil
12.1.5.1. Market Type and projections, 2015 - 2027 (USD Billion)
12.1.5.2. Brazil Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
12.1.5.3. Brazil Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
12.1.6. Argentina
12.1.6.1. Market Type and projections, 2015 - 2027 (USD Billion)
12.1.6.2. Argentina Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
12.1.6.3. Argentina Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
12.1.7. Rest of South America
12.1.7.1. Market Type and projections, 2015 – 2027
12.1.7.2. Rest of South America Vaginitis Therapeutics Market Overview, By Product, 2015 - 2027 (USD Billion)
12.1.7.3. Rest of South America Vaginitis Therapeutics Market Overview, By Type, 2015 - 2027 (USD Billion)
Chapter 13. Competitive Landscape
13.1. Competitive environment, 2020
13.2. Strategic framework
13.2.1. Partnership/agreement
13.2.2. Expansion
13.2.3. Mergers & Acquisitions
13.2.4. New Type development
Chapter 14. Key Vendor Analysis
14.1. Pfizer, Inc.
14.1.1. Company overview
14.1.2. Financial performance
14.1.3. Product Benchmarking
14.1.4. Recent initiatives
14.1.5. SWOT analysis
14.2. Merck & Co.
14.2.1. Company overview
14.2.2. Financial performance
14.2.3. Product Benchmarking
14.2.4. Recent initiatives
14.2.5. SWOT analysis
14.3. Bayer AG
14.3.1. Company overview
14.3.2. Financial performance
14.3.3. Product Benchmarking
14.3.4. Recent initiatives
14.4. Lupin Pharmaceuticals, Inc.
14.5. Symbiomix Therapeutics, Inc.
14.6. Mission Pharmacal Company
14.7. Abbott Laboratories
14.8. GlaxoSmithKline plc
14.9. Sanofi
14.10. Novartis AG
Chapter 15. Vaginitis Therapeutics Market Cost Analysis
15.1. Vaginitis Therapeutics Market Key Type Analysis
15.1.1. Key Type
15.1.2. Price Trend of Key Type
15.1.3. Key Suppliers of Type
15.1.4. Market Concentration Rate of Type
15.1.5. Labor Cost
Chapter 16. Sourcing Strategy and Downstream Buyers
16.1. Vaginitis Therapeutics Market Chain Analysis
16.2. Upstream Type Sourcing
16.3. Vaginitis Therapeutics Market Major Manufacturers in 2021
16.4. Downstream Buyers
Chapter 17. Marketing Strategy Analysis, Distributors/Traders
17.1. Marketing Channel
17.1.1. Direct Marketing
17.1.2. Indirect Marketing
17.1.3. Marketing Channel Development Trend
17.2. Market Positioning
17.2.1. Pricing Strategy
17.2.2. Brand Strategy
17.2.3. Target Client
17.3. Distributors/Traders List
Chapter 18. Market Effect Factors Analysis
18.1. Technology Progress/Risk
18.1.1. Substitutes Threat
18.1.2. Technology Progress in Related Type
18.2. Consumer Needs/Customer Preference Change
18.3. Economic/Political Environmental Change
Chapter 19. Future Outlook of the Market
Disclaimer
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Vaginitis Therapeutics Market share, By Product, 2020 & 2027 (%)
10. Global Vaginitis Therapeutics Market share, by Anti-Fungal, By Product, 2015 - 2027 (USD Billion)
11. Global Vaginitis Therapeutics Market share, by Anti-Bacterial, By Product, 2015 - 2027 (USD Billion)
12. Global Vaginitis Therapeutics Market share, by Hormonal, By Product, 2015 - 2027 (USD Billion)
13. Global Vaginitis Therapeutics Market share, By Type, 2020 & 2027 (%)
14. Global Vaginitis Therapeutics Market share, by Over-The-Counter (OTC), By Type, 2015 - 2027 (USD Billion)
15. Global Vaginitis Therapeutics Market share, by Prescription (Rx), By Type 2015 - 2027 (USD Billion)
16. Global Vaginitis Therapeutics Market share, by region, 2020 & 2027 (%)
17. Global Vaginitis Therapeutics Market share, by region, 2015 - 2027(USD Billion)
18. North America Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
19. North America Vaginitis Therapeutics Market share, by Countries, 2020 & 2027 (%)
20. U.S. Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
21. Canada Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
22. Mexico Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
23. Europe Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
24. Europe Vaginitis Therapeutics Market share, by Countries, 2020 & 2027 (%)
25. Spain Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
26. UK Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
27. Italy Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
28. Germany Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
29. France Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
30. Rest of Europe Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
31. Asia-Pacific Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
32. Asia-Pacific Vaginitis Therapeutics Market share, by Countries, 2020 & 2027 (%)
33. China Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
34. India Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
35. Australia Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
36. Japan Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
37. Rest of Asia-Pacific Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
38. Middle East & Africa Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
39. Middle East & Africa Vaginitis Therapeutics Market share, by Countries, 2020 & 2027 (%)
40. GCC Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
41. South Africa Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
42. Rest Of Middle East & Africa Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
43. South America Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
44. Brazil Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
45. Mexico Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
46. Argentina Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
47. Rest Of South America Vaginitis Therapeutics Market, 2015 - 2027(USD Billion)
List of Tables
1. Impact of Market drivers
2. Impact of Market restraints
3. Global Vaginitis Therapeutics Market, 2015-2027 (USD Billion)
4. Vaginitis Therapeutics requirement, by country, 2015-2027, (USD Billion)
5. North America Vaginitis Therapeutics Market, By Product, 2015-2027 (USD Billion)
6. North America Vaginitis Therapeutics Market, By Type, 2015-2027 (USD Billion)
7. Europe Vaginitis Therapeutics Market, By Product, 2015-2027 (USD Billion)
8. Europe Vaginitis Therapeutics Market, By Type, 2015-2027 (USD Billion)
9. Asia Pacific Vaginitis Therapeutics Market, By Product, 2015-2027 (USD Billion)
10. Asia Pacific Vaginitis Therapeutics Market, By Type, 2015-2027 (Revenue, USD Billion)
11. Middle East & Africa Vaginitis Therapeutics Market, By Product, 2015-2027 (USD Billion)
12. Middle East & Africa Vaginitis Therapeutics Market, By Type, 2015-2027 (USD Billion)
13. South America Vaginitis Therapeutics Market, By Product, 2015-2027 (USD Billion)
14. South America Vaginitis Therapeutics Market, By Type, 2015-2027 (USD Billion)
15. Global Vaginitis Therapeutics Market, Company Market Share, 2020 - 2027 (%)
16. Pfizer, Inc.: Product Benchmarking
17. Pfizer, Inc.: Financial Performance
18. Merck & Co. : Product Benchmarking
19. Merck & Co. : Financial Performance
20. Bayer AG. : Product Benchmarking
21. Bayer AG. : Financial Performance
22. Lupin Pharmaceuticals, Inc. :Product Benchmarking
23. Lupin Pharmaceuticals, Inc. :Financial Performance
24. Symbiomix Therapeutics, Inc.: Product Benchmarking
25. Symbiomix Therapeutics, Inc.: Financial Performance
26. Mission Pharmacal Company.: Product Benchmarking
27. Mission Pharmacal Company.: Financial Performance
28. Abbott Laboratories.: Product Benchmarking
29. Abbott Laboratories: Financial Performance
30. GlaxoSmithKline plc..: Product Benchmarking
31. GlaxoSmithKline plc.: Financial Performance
32. Sanofi.: Product Benchmarking
33. Sanofi.: Financial Performance
34. Novartis AG.: Product Benchmarking
35. Novartis AG.: Financial Performance
The Leading Key Players in Vaginitis Therapeutics Market
Pfizer Inc.
Merck & Co.
Novartis AG
Bayer AG
Lupin Pharmaceuticals Inc.
Symbiomix Therapeutics Inc.
Mission Pharmacal Company
Abbott Laboratories
GlaxoSmithKline plc
Sanofi
Novartis AG.
